Literature DB >> 27889572

SMAD About Hepatitis C Virus Cell Entry and Liver Disease.

Che C Colpitts1, Thomas F Baumert2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27889572      PMCID： PMC5315220          DOI： 10.1053/j.gastro.2016.11.029

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   33.883


× No keyword cloud information.
  13 in total

1.  Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.

Authors:  Jennifer M MacArthur; Joseph R Bishop; Kristin I Stanford; Lianchun Wang; André Bensadoun; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.

Authors:  Mark S Roberts; Fasiha Kanwal; Jagpreet Chhatwal; Xiaojie Wang; Turgay Ayer; Mina Kabiri; Raymond T Chung; Chin Hur; Julie M Donohue
Journal:  Hepatology       Date:  2016-06-01       Impact factor: 17.425

Review 3.  Heparan sulfate proteoglycans.

Authors:  Stephane Sarrazin; William C Lamanna; Jeffrey D Esko
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

4.  Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.

Authors:  Fang Zhang; Catherine Sodroski; Helen Cha; Qisheng Li; T Jake Liang
Journal:  Gastroenterology       Date:  2016-09-30       Impact factor: 22.682

5.  Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization.

Authors:  Wan-Jong Kuo; Michelle A Digman; Arthur D Lander
Journal:  Mol Biol Cell       Date:  2010-09-22       Impact factor: 4.138

6.  Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections.

Authors:  Che C Colpitts; Eloi R Verrier; Thomas F Baumert
Journal:  ACS Infect Dis       Date:  2015-05-18       Impact factor: 5.084

7.  Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.

Authors:  Stephanie Arndt; Eva Wacker; Christoph Dorn; Andreas Koch; Michael Saugspier; Wolfgang E Thasler; Arndt Hartmann; Anja Katrin Bosserhoff; Claus Hellerbrand
Journal:  Gut       Date:  2014-07-10       Impact factor: 23.059

8.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Peter Richardson; Jennifer Kramer
Journal:  Hepatology       Date:  2016-04-19       Impact factor: 17.425

9.  Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle.

Authors:  Qisheng Li; Yong-Yuan Zhang; Stephan Chiu; Zongyi Hu; Keng-Hsin Lan; Helen Cha; Catherine Sodroski; Fang Zhang; Ching-Sheng Hsu; Emmanuel Thomas; T Jake Liang
Journal:  PLoS Pathog       Date:  2014-05-22       Impact factor: 6.823

Review 10.  Hepcidin and the iron enigma in HCV infection.

Authors:  Urania Georgopoulou; Alexios Dimitriadis; Pelagia Foka; Eirini Karamichali; Avgi Mamalaki
Journal:  Virulence       Date:  2014-03-13       Impact factor: 5.882
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.